Viking Therapeutics Announces Pricing of $250 Million Public Offering of Common Stock

SAN DIEGO, March 29, 2023 /PRNewswire/ — Viking Therapeutics, Inc. (“Viking”) (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the pricing of its underwritten public offering of…

Click here to view original post